Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

1. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. (PubMed)

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been expressed. This study investigated whether CT-P13 is non (...) -inferior to infliximab in patients with Crohn's disease who were naive to biological therapy.In this randomised, multicentre, double-blind, phase 3 non-inferiority study, we enrolled patients with active Crohn's disease who had not responded to, or were intolerant to, non-biological treatments. Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. Patients received 5 mg

2019 Lancet

2. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. (PubMed)

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. CT-P13 is a biosimilar of the reference product (RP) infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of Crohn disease (CD) on that basis, without specific studies examining its effects in CD.To compare the effectiveness and safety of CT-P13 and RP in infliximab-naive patients with CD.Comparative equivalence cohort (...) study.Système National des Données de Santé (SNDS), a French nationwide health administrative database (1 March 2015 to 30 June 2017).5050 infliximab-naive patients with CD who were older than 15 years, had started treatment with RP (n = 2551) or CT-P13 (n = 2499), and had no other indications for infliximab.The primary outcome was a composite end point of death, CD-related surgery, all-cause hospitalization, and reimbursement of another biologic therapy. Equivalence was defined as a 95% CI of the hazard

2018 Annals of Internal Medicine

3. Infliximab

Infliximab Top results for infliximab - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for infliximab The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

4. Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease (PubMed)

Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease To report a case of pediatric Vogt-Koyanagi-Harada (VKH) successfully treated with infliximab and methotrexate for ten years.A 9-year-old Hispanic girl with VKH disease, was successfully treated with oral methotrexate 15 mg/week and oral prednisone 40 mg/day (1mg/kg/day). But when oral prednisone was tapered to 10 mg/day over a 3-month period, inflammation recurred. Patient was considered as corticosteroid-dependent (...) thus infliximab 7mg/kg/pulse was started on days 0, 15, 60 and every 60 days thereafter. Six months after, infliximab was increased to 10mg/kg/pulse as cells in the anterior chamber were still observed. After four months of treatment, ocular inflammation was fully controlled, oral prednisone was tapered to discontinuation over a period of 10 months and methotrexate was maintained at 15 mg/week. At 1-year follow up, infliximab was reduced to 6 mg/kg/pulse as patient remained stable on examination

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

5. Renflexis - Infliximab

Renflexis - Infliximab Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include

2018 Health Canada - Drug and Health Product Register

6. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Zessly is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications

2018 European Medicines Agency - EPARs

7. Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis (PubMed)

Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-α agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression (...) , and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-α agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still's disease.

Full Text available with Trip Pro

2018 European journal of rheumatology

8. Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy

Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password (...) If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × December 2017. Volume 13. Number 4 Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s privacy

2018 Evidencias en Pediatría

9. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction (PubMed)

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series (...) (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination

Full Text available with Trip Pro

2018 mSystems

10. infliximab (TBC)

infliximab (TBC) infliximab | CADTH.ca Find the information you need infliximab infliximab Last Updated: April 30, 2018 Result type: Reports Project Number: SE0532-000 Product Line: Generic Name: infliximab Brand Name: Renflexis Manufacturer: Merck Canada Inc. Indications: rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis (...) , gastrointestinal tract, musculoskeletal, infliximab; SEB; subsequent entry biologic; subsequent entry biologics Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

11. Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator (PubMed)

Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator Three patients affected by Behçet's disease (BD) with severe uveitis and neurological involvement in stable clinical remission and who rapidly relapsed after switching from reference infliximab (re-IFX) to biosimilar infliximab (bio-IFX) are reported. In order to observe the rules of local health authorities, two males and one female (38, 26, and 40 years old

Full Text available with Trip Pro

2017 European journal of rheumatology

12. Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab (PubMed)

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab Lymphoproliferative disorders, particularly non-Hodgkin's and Hodgkin's lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association.We report

Full Text available with Trip Pro

2017 GE Portuguese journal of gastroenterology

13. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. (PubMed)

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive (...) biosimilar CT-P13 regarding efficacy, safety, and immunogenicity.The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up. Adult patients on stable treatment with infliximab originator treated in a hospital setting for at least 6 months were eligible for participation. Patients with informed consent were randomised in a 1:1 ratio to either continued infliximab originator or to switch to CT-P13 treatment, with unchanged dosing regimen. Data were collected

2017 Lancet

14. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product (PubMed)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory arthritis switched from reference product in our center.In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval.Around 34 patients (...) with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12.9), mean disease duration 14.79 years (9.7), median duration on infliximab 57 months, and two-thirds on oral disease-modifying antirheumatic drugs. There was no difference in efficacy or safety in the first 6 months of therapy. By the end of 2015, the mean follow-up on biosimilar infliximab was 15.8 (standard deviation=6.3) months. Our results showed

Full Text available with Trip Pro

2017 Open access rheumatology : research and reviews

15. Refractory extrapulmonary sarcoidosis: infliximab

Refractory extrapulmonary sarcoidosis: infliximab Refr Refractory e actory extr xtrapulmonary sarcoidosis: apulmonary sarcoidosis: infliximab infliximab Evidence summary Published: 17 January 2017 nice.org.uk/guidance/es4 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2017. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information (...) . Summary Because no randomised controlled trials were identified, this evidence summary includes 10 observational studies that assessed the effects of infliximab for treating active, unstable extrapulmonary sarcoidosis in people who had found corticosteroids and other immunosuppressants to be ineffective, or who could not tolerate these treatments (refractory sarcoidosis). The studies included 155 cases of refractory extrapulmonary sarcoidosis, primarily in the nervous system (34%) or skin (25%), who

2017 National Institute for Health and Clinical Excellence - Advice

16. Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Switching from Innovator to Biosimilar (...) (Subsequent Entry) Infliximab: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: January 18, 2017 Project Number: RC0836-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with rheumatoid arthritis? What is the clinical effectiveness and safety of switching from innovator infliximab

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Pulmonary sarcoidosis: infliximab

Pulmonary sarcoidosis: infliximab Pulmonary sarcoidosis: infliximab Pulmonary sarcoidosis: infliximab Evidence summary Published: 20 December 2016 nice.org.uk/guidance/es2 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2016 . See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary A randomised controlled trial (RCT (...) ) found that, in 138 people with stable stable pulmonary sarcoidosis, infliximab improved mean percent of predicted forced vital capacity (FVC) at week 24 by 2.5% compared with placebo; this was statistically significant. However, although some individual patients with stable disease, especially those with more severe symptoms, may see greater benefits, it is unclear whether this small, average improvement in this disease-oriented outcome is clinically important on a population basis. There were

2017 National Institute for Health and Clinical Excellence - Advice

18. Infliximab (REMSIMA)

Infliximab (REMSIMA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include

2017 Health Canada - Drug and Health Product Register

19. Infliximab-Induced Lupus: A Case Report (PubMed)

Infliximab-Induced Lupus: A Case Report We report the case of a 48-year-old, leukodermic female diagnosed with ulcerative proctitis for 4 years and latent tuberculosis. She was allergic to salicylates and had a minor allergic reaction to infliximab (rash, vertigo, and headache). Thereafter, she started azathioprine (2.5 mg/kg/day). She maintained intravenous infliximab, together with prophylaxis with clemastine and hydrocortisone, due to the steroid-dependent proctitis. The therapy (...) was continued every 8 weeks with anti-tumor necrosis factor for about 3 years. The analytical evaluation when she was diagnosed with ulcerative proctitis (February 2011) showed negative antinuclear antibodies (ANA), double-stranded-DNA antibodies (anti-dsDNA), antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies, and a positive outer membrane protein antibody. About 2 years and 6 months after starting infliximab (November 2013), the patient complained of inflammatory

Full Text available with Trip Pro

2016 GE Portuguese journal of gastroenterology

20. Infliximab (Remicade Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease

Infliximab (Remicade Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Infliximab (IFX) (Remicade; Janssen Biotech Inc.) is a recombinant chimeric human-murine immunoglobulin G1 monoclonal antibody designed to target and block tumor necrosis factor-alpha (TNF-?) and, thereby, reduce inflammation and associated sequelae. For pediatric Crohn disease (CD), IFX

2016 Health Technology Assessment (HTA) Database.